Inhaled Recombinant Non-immunogenic Staphylokinase vs Placebo in Patients With COVID-19 - FORRIF Trial
Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Objective: to evaluate the tolerability, safety and efficacy of inhaled usage of the
Recombinant Non-immunogenic Staphylokinase (Fortelyzin®) vs placebo in patients with
COVID-19.